An independent judging panel will select three finalists from the submissions.
The Society for Clinical Research Sites (SCRS), a global trade organization for clinical research sites, announced that it is accepting submissions for its annual Site Patient Recruitment Innovation Award (SPRIA), which recognizes sites that employ innovative strategies to achieve enrollment success. An independent judging panel will select three finalists from the submissions. The finalists will be invited to attend the Site Solutions Summit with a complimentary registration. At the summit, the finalists will present their plans to an audience of executives from sites, sponsors, and CROs. The judging panel then will determine the winner. Nominations forms can be downloaded on the Global Site Solutions Summit website. Completed form should be sent to SPRIA@myscrs.org by July 31, 2015.
The Global Site Solutions Summit takes place October 8-11, at Amelia Island, FL.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.